Kernicterus:ThePreventableBrainInjury

Jaundice in a newborn is common and, in most cases, entirely benign. As the infant's body transitions to the adult pattern of red-blood-cell turnover, bilirubin — a breakdown product of hemoglobin — rises and then falls over the first week of life. In the vast majority of infants, the liver clears bilirubin without difficulty and the yellowing resolves on its own.

The danger arises when bilirubin rises higher than the infant's liver can clear — often in the setting of specific risk factors — and crosses into a range where it becomes neurotoxic. Unconjugated (indirect) bilirubin that accumulates above certain thresholds crosses the blood-brain barrier and deposits in the basal ganglia, hippocampus, and cranial-nerve nuclei in the brainstem. The result is a very specific pattern of permanent injury.

The chronic form has a recognizable pattern — one reason kernicterus is so legally identifiable. Unlike the broader category of cerebral palsy, the specific combination of choreoathetosis, hearing loss, and gaze abnormalities points directly at bilirubin as the cause. When a child presents with that tetrad and a documented history of severe neonatal jaundice, the medical literature supports the causation argument cleanly.

The modern screening framework is well-established and widely distributed. The American Academy of Pediatrics (AAP) publishes clinical practice guidelines for management of hyperbilirubinemia in the newborn, updated most recently in 2022. The CDC operates a public-education campaign specifically focused on kernicterus prevention, emphasizing that the condition is preventable with timely screening and treatment.

The screening process has specific components, and the standard of care requires each of them:

• Universal pre-discharge bilirubin. Every newborn should have a transcutaneous or serum bilirubin measured before discharge. Visual estimation of jaundice is unreliable and is explicitly inadequate on its own.
• Plotting on the hour-specific nomogram. A bilirubin of 10 mg/dL at 24 hours of age means something very different from the same value at 96 hours. The hour-specific nomogram places the value in context — low-risk zone, low-intermediate, high-intermediate, or high-risk.
• Identification of high-risk infants. Late preterm (35 to 37 weeks), infants with poor breastfeeding, infants with ABO or Rh incompatibility, infants with known G6PD deficiency, infants whose siblings required phototherapy, and East Asian ethnicity all confer elevated risk. These infants need closer follow-up than their peers.
• Pediatric follow-up within 24 to 72 hours. Every newborn should be seen within that window. For high-risk infants, follow-up should be on the earlier end.
• Parental education at discharge. Written and verbal guidance on recognizing worsening jaundice — when to call, what to watch for — with documentation that the family received it.

When all of these steps are documented and the infant's bilirubin trajectory is tracked, kernicterus is essentially preventable. When any of them is skipped, the door opens.

Most kernicterus cases in the United States share a small number of common failure patterns. In medical malpractice review, these are the things the records are reviewed for:

• Pre-discharge screening omitted. The hospital discharged the infant without drawing a bilirubin level. This is increasingly rare at hospitals with order-set protocols but still occurs, especially at smaller facilities.
• Level drawn but not interpreted on the nomogram. The result sits in the chart as a number with no indication that anyone plotted it against the hour-specific thresholds. A bilirubin of 14 mg/dL may be reassuring at 96 hours and alarming at 24 hours — the number alone does not tell you which.
• High-risk infant discharged without follow-up. The infant had risk factors that should have triggered a 24-hour follow-up, but the discharge summary arranged a 5-day or 7-day visit — or none at all.
• Follow-up visit without bilirubin recheck. The infant was seen, jaundice was noted in the chart, and no level was drawn. Visual estimation was relied on. The infant went home and returned two days later with bilirubin in the kernicterus range.
• Parental report dismissed. The parents called to report worsening jaundice or lethargy, and the phone-triage response was reassurance. No rapid appointment, no level drawn.
• Elevated level not treated in time. A high result was reported to the pediatrician who did not send the infant to the emergency department or hospital for phototherapy, or who delayed for hours when the level required exchange transfusion.

Each of these breakdowns leaves a specific evidentiary footprint — or a specific absence of one. A competent malpractice review reconstructs the timeline from every record point in the infant's care and identifies where the escape route from kernicterus was available but not taken.

Phototherapy is simple, well-tolerated, and effective. Infants are placed under blue lights, with eyes covered and most of the skin exposed, typically in the hospital nursery. The light converts bilirubin in the skin into isomers that are water-soluble and can be excreted in the urine and stool. Serial bilirubin levels are drawn every 4 to 12 hours to confirm that the level is falling. Most infants respond within 24 to 48 hours.

Exchange transfusion is reserved for bilirubin levels at or above the exchange-transfusion threshold on the AAP nomogram — typically in infants presenting with signs of acute bilirubin encephalopathy or with levels that are not responding to intensive phototherapy. The procedure replaces the infant's blood volume with donor blood over a few hours, rapidly removing bilirubin and replenishing albumin to bind what remains. It is an ICU-level procedure but, performed competently and in time, it prevents kernicterus.

Neither treatment fails often. The malpractice question is almost never whether phototherapy or exchange transfusion worked — it is whether they were started in time. Delays of even 12 to 24 hours, when bilirubin is rising steeply, can be the difference between a healthy child and a child with kernicterus.

Kernicterus cases are, in litigation terms, relatively clean on causation. The characteristic tetrad of findings — choreoathetoid cerebral palsy, auditory neuropathy or hearing loss, upgaze palsy, and dental enamel abnormalities — points at bilirubin in a way few other conditions do. MRI findings are often specific as well, with abnormal signal in the globus pallidus and subthalamic nuclei.

The harder question is usually whether any individual provider breached the standard of care. The defense in a kernicterus case will often argue that the screening protocol was followed, that the follow-up visit was offered (even if not attended), that the family was counseled on signs of jaundice at discharge, or that the infant's bilirubin trajectory was atypical. A careful plaintiff's case reconstructs every provider touchpoint — hospital discharge, pediatrician visits, after-hours calls, lactation consults — and identifies which touchpoints should have caught the rising level and did not.

Florida Statute § 766.102 requires a corroborating expert affidavit from a board-certified specialist in the same specialty as each defendant before suit can be filed. The pre-suit investigation period is 90 days.

A severe kernicterus case carries lifetime care needs similar in magnitude to severe cerebral palsy cases generally — around-the-clock attendant care, ongoing therapy, adaptive communication technology, hearing aids or cochlear implants, and extensive dental reconstruction over decades. A certified life-care planner and an economist project those costs over the child's life expectancy, discounted to present value.

Recoverable categories in Florida include all past and future medical expenses, the full projected life-care plan, lost earning capacity for a child whose impairments limit vocational options, non-economic damages for pain and suffering and loss of enjoyment of life (now uncapped after North Broward Hospital District v. Kalitan, 219 So. 3d 49 (Fla. 2017)), and loss of consortium for the parents. These are serious cases, actively defended, and no family should settle one without experienced trial counsel and a complete life-care plan in hand.